Journal article icon

Journal article

Medicines adaptive pathways to patients: Why, when, and how to engage?

Abstract:
Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life‐span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life‐span. These considerations are of relevance for regulatory and access pathways that strive to address the “evidence vs. access” conundrum.
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1002/cpt.1121

Authors


Expand authors...
Publisher:
Wiley Publisher's website
Journal:
Clinical Pharmacology and Therapeutics Journal website
Volume:
105
Issue:
5
Pages:
1148-1155
Publication date:
2018-09-11
Acceptance date:
2018-05-01
DOI:
EISSN:
1532-6535
ISSN:
0009-9236
Pubs id:
pubs:857634
URN:
uri:1d6d5c98-4142-404d-9fe2-11fcf52d9167
UUID:
uuid:1d6d5c98-4142-404d-9fe2-11fcf52d9167
Local pid:
pubs:857634
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP